PACIRA BIOSCIENCES, INC. Debt Conversion, Converted Instrument, Amount
PACIRA BIOSCIENCES, INC. (PCRX) reported Debt Conversion, Converted Instrument, Amount of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2025-02-27
- PACIRA BIOSCIENCES, INC. debt conversion, converted instrument, amount for the quarter ending 2023-12-31 was $0.00.
- PACIRA BIOSCIENCES, INC. debt conversion, converted instrument, amount for the quarter ending 2023-09-30 was $0.00.
- PACIRA BIOSCIENCES, INC. debt conversion, converted instrument, amount for the quarter ending 2022-12-31 was $0.00.
- PACIRA BIOSCIENCES, INC. debt conversion, converted instrument, amount for the quarter ending 2022-09-30 was $0.00.
- PACIRA BIOSCIENCES, INC. debt conversion, converted instrument, amount for fiscal 2024 was $0.00.
- PACIRA BIOSCIENCES, INC. debt conversion, converted instrument, amount for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- PACIRA BIOSCIENCES, INC. debt conversion, converted instrument, amount for fiscal 2022 was $3.04M.
- PACIRA BIOSCIENCES, INC. debt conversion, converted instrument, amount for fiscal 2021 was $0.00.
| Period end | Debt Conversion, Converted Instrument, Amount 3 month | Debt Conversion, Converted Instrument, Amount 6 month | Debt Conversion, Converted Instrument, Amount 9 month | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-27 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 derived: sum of 2 quarters · filed 2025-02-27 | $0.00 10-K · filed 2025-02-27 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $0.00 10-Q · filed 2023-11-02 | ||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-02 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $0.00 derived: sum of 2 quarters · filed 2025-02-27 | $3.04M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $3.04M 10-Q · filed 2023-11-02 | ||
| 2022-06-30 | $3.04M 10-Q · filed 2023-08-02 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $0.00 derived: sum of 2 quarters · filed 2024-02-29 | $0.00 10-K · filed 2024-02-29 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-03 | |||
| 2013-12-31 | $0.00 10-K · filed 2014-02-25 | |||
| 2012-12-31 | $0.00 10-K · filed 2014-02-25 | |||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $0.00 derived: sum of 2 quarters · filed 2014-02-25 | $0.00 derived: sum of 3 quarters · filed 2014-02-25 | $51.22M 10-K · filed 2014-02-25 |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-01 | $0.00 derived: sum of 2 quarters · filed 2012-11-01 | $51.22M 10-Q · filed 2012-11-01 | |
| 2011-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | $51.22M 10-Q · filed 2012-08-09 | ||
| 2011-03-31 | $51.22M 10-Q · filed 2012-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |